<DOC>
	<DOCNO>NCT00267189</DOCNO>
	<brief_summary>The purpose study assess effect everolimus initiation together reduction discontinuation calcineurin inhibitor ( CNI ) renal function maintenance liver transplant recipients CNI-related renal impairment , maintain efficacy .</brief_summary>
	<brief_title>RESCUE Study - Everolimus Liver Transplantation Recipients With Renal Insufficiency</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Inclusion criterion Male female 18 70 year old Patient undergone primary liver transplantation 12 60 month ago cadaveric live donor Patient calculate GFR ≤ 60 ≥ 20mL/min Patient receive tacrolimus C0h level ≥ 3 ≤ 8 ng/mL Neoral® C0h level ≥ 50 ≤ 150 ng/mL C2h level ≥ 250 ng/mL ≤ 650 ng/mL without follow ( MPA AZA steroid ) Patient willing capable give write informed consent study participation able participate study 6 month Patient allograft biopsy contraindicate Female capable become pregnant must negative pregnancy test prior randomization require practice medically approve method birth control duration study Exclusion criterion Recipient multiple solid organ transplant Patient dialysis Patient identifiable cause renal dysfunction CNI toxicity Patient proteinuria ≥ 1.0 g/24h Patient acute rejection within 6 month prior randomization Patient platelet count ≤ 50,000/mm³ white blood cell count ≤ 2,000/mm³ hemoglobin value ≤ 8 g/dL Undergone liver transplantation hepatocellular carcinoma sign recurrence ; Severe graft dysfunction ; HCV positive patient need active antiviral treatment HIV positive patient Patient breast feed Patient current severe systemic infection Patient receive unlicensed drug therapy within one month prior study entry Presence hypersensitivity drug similar everolimus ( e.g . macrolides ) Use immunosuppressive drug tacrolimus/cyclosporine microemulsion , steroid , azathioprine mycophenolic acid Additional protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Liver transplantation , everolimus , calcineurin inhibitor , renal function</keyword>
</DOC>